HR and breast cancer: Cases were defined as patients with TNBC (hormone receptor [HR]−/human epidermal growth factor receptor 2 [HER2]−), and controls were patients with other subtypes of BC (HR−/HER2+, HR+/HER2−, and HR+/HER2+).